Gut Healing Protocol
Overview
A targeted oral peptide protocol for gastrointestinal repair, addressing gastric ulcers, intestinal hyperpermeability (leaky gut), IBD (Crohn's and ulcerative colitis), and gut dysbiosis-related inflammation. Oral administration delivers peptides directly to the gut lumen — BPC-157 and KPV both retain significant biological activity when taken orally, making them ideal for mucosal delivery. The KLOW blend refers to a compounded oral formulation typically containing KPV. Expected outcomes include reduced gut inflammation, healed mucosal lining, normalized intestinal permeability, and symptomatic relief from gut conditions.
Components
| Peptide | Dose | Frequency | Duration |
|---|---|---|---|
| BPC-157 | 250-500 mcg oral | Once daily, empty stomach | 4-8 weeks |
| KPV | 200-500 mcg oral | Twice daily (BID), empty stomach | 4-8 weeks |
Optional additions:
| Peptide | Dose | Frequency | Duration |
|---|---|---|---|
| VIP | 50-100 mcg SubQ | 2-3x/week | 4-8 weeks |
| LL-37 | 100 mcg SubQ | 2-3x/week | 4 weeks |
Administration
- BPC-157 oral: Dissolve in small amount of water or take as capsule; must be taken on empty stomach (30-60 minutes before eating or 2+ hours after); empty stomach essential for contact with gastric and intestinal mucosa
- KPV oral: Capsule or dissolved in water; empty stomach preferred; can be staggered with BPC-157 (e.g., BPC-157 first thing in AM, KPV mid-morning and evening)
- VIP SubQ: For refractory IBD or mast cell disorders; requires physician involvement; refrigerate reconstituted peptide
- KLOW blend: Compounded oral formulation per pharmacy protocol; follow provider's dosing instructions
Cycling
- Acute phase (active flare, ulcer): 8 weeks at full dose
- Maintenance (prevention, leaky gut optimization): 4-8 weeks on / 4 weeks off; or low-dose daily BPC-157 (250mcg) ongoing
- Reassess symptoms and inflammatory markers at each cycle end
Expected Timeline
- Week 1: Reduced gut pain, bloating, and urgency; mucosal inflammation beginning to resolve
- Week 2-3: Measurable improvement in symptoms; some patients experience significant relief within 2 weeks
- Week 4: Substantial mucosal repair; intestinal permeability tests (if used) showing normalization
- Week 6-8: Near-complete resolution of active gut inflammation; structural mucosal healing advanced
Monitoring
- Symptom diary: pain, bloating, stool frequency and quality (Bristol scale), urgency
- Calprotectin (stool test) at baseline and 8 weeks — marker of gut inflammation
- Zonulin (leaky gut marker) if available
- Endoscopy or colonoscopy at physician's discretion to confirm mucosal healing
- Track NSAID use — BPC-157 may allow NSAID dose reduction (coordinate with prescribing physician)
Contraindications
- Active GI malignancy
- Recent GI surgery (coordinate timing with surgical team)
- Known hypersensitivity to any component
- Pregnancy or breastfeeding
Sources
#protocol #gut #IBD #ulcer #leakygut #BPC157 #KPV #KLOW #mucosal